February 12th 2025
The median duration of response was 47.8 months among patients who achieved an initial complete response.
Dr. Emamekhoo on how his institute is addressing the cancer drug shortage
July 19th 2023“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.
Dr. Kamran on current research into predictive factors of response to bladder-preserving treatment
June 27th 2023"There are a lot of exciting data that are coming out, and, of course, a lot of physicians and physician-scientists [who] are interested in these questions, and we’re working on that," says Sophia C. Kamran, MD.
Financial toxicity is a growing concern in urologic oncology
June 23rd 2023"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Managing recurrence following bladder-sparing treatment
June 23rd 2023"If there’s recurrence of muscle-invasive bladder cancer within the bladder, you can perform salvage cystectomy at that point…. It is a bit more complex, so it’s great to have a high-volume surgeon who has performed these before," says Sophia C. Kamran, MD.
Bladder-sparing treatments show noninferior OS vs radical cystectomy in BCG-unresponsive NMIBC
June 19th 2023“Our results suggest that bladder-sparing treatments may be a safe approach in selected patients. Survival outcomes were not inferior compared to early radical cystectomy," says Wei Shen Tan, MD.